Lindbrook Capital, LLC - RECURSION PHARMACEUTICALS IN ownership

RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 158 filers reported holding RECURSION PHARMACEUTICALS IN in Q2 2023. The put-call ratio across all filers is 0.96 and the average weighting 1.1%.

Quarter-by-quarter ownership
Lindbrook Capital, LLC ownership history of RECURSION PHARMACEUTICALS IN
ValueSharesWeighting
Q2 2024$4,778
+95.6%
637
+160.0%
0.00%
Q1 2024$2,443
+1.1%
2450.0%0.00%
Q4 2023$2,416
-30.1%
245
-45.8%
0.00%
Q3 2023$3,458
+89.0%
452
+84.5%
0.00%
Q2 2023$1,830
+83.0%
245
+100.8%
0.00%
Q3 2022$1,0001220.00%
Other shareholders
RECURSION PHARMACEUTICALS IN shareholders Q2 2023
NameSharesValueWeighting ↓
Data Collective IV GP, LLC 5,941,120$45,806,03548.11%
Kinnevik AB (publ) 7,653,061$59,005,10033.28%
MV Management XI, L.L.C. 1,971,908$15,203,41126.45%
MIC Capital Management UK LLP 8,451,758$65,163,05712.86%
ArchPoint Investors 1,114,626$8,593,7664.07%
HARVARD MANAGEMENT CO INC 1,509,254$11,636,3481.44%
PLATINUM INVESTMENT MANAGEMENT LTD 2,710,339$20,896,7140.80%
Duquesne Family Office 1,385,950$10,685,6750.53%
ALLEN OPERATIONS LLC 217,657$1,678,1350.45%
Artal Group S.A. 960,204$7,4030.41%
View complete list of RECURSION PHARMACEUTICALS IN shareholders